On March 17, 2022 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, reported that preclinical data supporting the ongoing development of its conditionally activated cytokine program will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting on April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana (Press release, CytomX Therapeutics, MAR 17, 2022, View Source [SID1234610255]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Type I interferons, as monotherapy or in combination with PD-(L)1 blockade, are powerful antitumor agents, but the toxicity of these therapies, including interferon alpha, can limit their clinical use. We are working to address this limitation with our conditionally activated cytokine program," said Marcia P. Belvin, Ph.D., senior vice president and head of research at CytomX Therapeutics. "At the upcoming AACR (Free AACR Whitepaper) Annual Meeting, we will report encouraging preclinical data that support the development of our conditionally activated interferon alpha-2b therapeutic candidate as a promising addition to current immunotherapy regimens, potentially expanding benefit to patients with typically unresponsive tumors. This program represents the leading edge of a broad initiative at CytomX towards enhancing the therapeutic window of multiple cytokines."
Details for the poster presentation are as follows:
Presentation Title: Probody-interferon-alpha 2b combines antitumor activity with improved tolerability
Abstract Number: 2071
Session Title: Immunomodulatory Agents and Interventions 1
Session Date and Time: Monday, April 11, 2022, 1:30 – 5:00 pm CT